This Article Full Text Full Text (PDF) All Versions of this Article: 34/1/145    most recent 09031936.00084808v1 Alert me when this article is cited Alert me if a correction is posted Permissions Request Permissions Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wang, Z. Articles by Raghunath, M. Search for Related Content PubMed PubMed Citation Articles by Wang, Z. Articles by Raghunath, M.

Suberoylanilide hydroxamic acid: a potential epigenetic therapeutic agent for lung fibrosis?

¹ Tissue Modulation Laboratory, Division of Bioengineering, Faculty of Engineering, ² Dept of Physiology, National University of Singapore, ⁵ NUS Tissue Engineering Program, Dept of Orthopedic Surgery, ⁶ Dept of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, ³ Institute of Pharmaceutical Sciences, University of Freiburg, Freiburg, Germany, and ⁴ Molecular Hepatology, School of Medicine and Pharmacology, Faculty of Medicine, Dentistry and Heath Sciences, The University of Western Australia, Perth, Australia.

CORRESPONDENCE: M. Raghunath, Division of Bioengineering, Faculty of Engineering, and Dept of Biochemistry, Yong Loo Lin School of Medicine, Division Office Block E3A #04-15, 7 Engineering Dr. 1, Singapore 117574. E-mail: bierm{at}nus.edu.sg

Keywords: Antifibrotic, collagen, fibroblast, histone deacetylase inhibitor, pulmonary fibrosis, suberoylanilide hydroxamic acid

Received: June 5, 2008
Accepted January 25, 2009

Pulmonary fibrosis represents a fatal stage of interstitial lung diseases of known and idiopathic aetiology. No effective therapy is currently available. Based on an indication-discovery approach we present novel in vitro evidence that the histone deacetylases inhibitor suberoylanilide hydroxamic acid (SAHA), an FDA approved anti-cancer drug, has antifibrotic and anti-inflammatory potential.

Human lung fibroblasts (fetal, adult and idiopathic adult pulmonary fibrosis) were treated with transforming growth factor (TGF)-β1 with or without SAHA. Collagen deposition, -smooth muscle actin (-SMA) expression, matrix metalloproteinase (MMP)1 activity, tissue inhibitor of MMP (TIMP)1 production, apoptosis and cell proliferation were assessed. Pro-inflammatory cytokines relevant to pulmonary fibrosis were assayed in SAHA-treated human peripheral blood mononuclear cells (PBMC) and its subpopulations.

SAHA abrogated TGF-β1 effects on all the fibroblast lines by preventing their transdifferentiation into -SMA positive myofibroblasts and increased collagen deposition without inducing apoptosis. However, MMP1 activity and TIMP1 production was modulated without a clear fibrolytic effect. SAHA also inhibited serum-induced proliferation of the fibroblast lines and caused hyperacetylation of -tubulin and histone. Cytokine secretion was inhibited from PBMC and lymphocytes at nonapoptotic concentrations.

Taken together, these data demonstrate combined antifibrotic and anti-inflammatory properties of SAHA, suggesting its therapeutic potential for pulmonary fibrosis.

This article has been cited by other articles:

				E. W. Bush and T. A. McKinsey Protein Acetylation in the Cardiorenal Axis: The Promise of Histone Deacetylase Inhibitors Circ. Res., February 5, 2010; 106(2): 272 - 284. [Abstract] [Full Text] [PDF]